	US 11,851,482 B2
	Anti-complement factor Bb antibodies and uses thereof
Sandip Panicker, South San Francisco, CA (US); Graham Parry, Cambridge, MA (US); Karen Sue Christopherson, San Mateo, CA (US); and Tony SangYoung Byun, Brisbane, CA (US)
Assigned to Genzyme Corporation, Cambridge, MA (US)
Filed by Bioverativ USA Inc., Waltham, MA (US)
Filed on Jan. 19, 2021, as Appl. No. 17/151,860.
Application 17/151,860 is a continuation of application No. 16/091,447, granted, now 10,934,347, previously published as PCT/US2017/025784, filed on Apr. 3, 2017.
Claims priority of provisional application 62/317,897, filed on Apr. 4, 2016.
Prior Publication US 2021/0221877 A1, Jul. 22, 2021
Int. Cl. C07K 16/18 (2006.01); C07K 16/40 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/18 (2013.01) [C07K 16/40 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)]

20 Claims

1. A humanized antibody that binds specifically to complement factor Bb, wherein the antibody comprises light chain complementarity determining regions (CDRs) of an antibody light chain variable (VL) region comprising amino acid sequence SEQ ID NO:30 and heavy chain CDRs of an antibody heavy chain variable (VH) region comprising amino acid sequence SEQ ID NO:31.